Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UNC to test new assist device for failed livers

12.03.2003




Prospects for surviving acute liver failure are very slim, and statistics place mortality as high as 90 percent. A liver transplant may be the only alternative before fatal complications set in, yet not enough donor organs are available to meet the demand.

But a new bio-artificial technology about to undergo clinical tests at the University of North Carolina at Chapel Hill and several other centers nationally may help extend the lives of those awaiting a donor liver and may even allow the damaged liver to heal itself completely.

Known by its acronym ELAD, the extracorporeal liver assist device is the first such technology to contain functioning human hepatocytes, liver cells that help sustain and support the work of the patient’s damaged and failed organ. Other liver assist systems use hepatocytes from pigs.



The new device is a closed system to which patients are tethered via a catheter inserted into a vein in the neck. After the blood is initially filtered, the remaining plasma goes through cartridges in the ELAD where the human hepatocytes help fulfill much of the liver’s 100 or so crucial functions, such as energy storage and regulation, bile production, blood detoxification, production of clotting factors and many essential proteins. The filtered blood and ELAD-treated plasma are returned to the patient.

Dr. Roshan Shrestha, associate professor of medicine and medical director of the liver transplantation program at UNC, said ELAD could provide two major benefits.

"This device could serve as a bridge to successful transplantation, helping to sustain patients awaiting a donor organ."

It also may enable complete recovery, he added.

"A remarkable feature of the liver is its capacity to regenerate. If we can sustain acute liver failure patients early on, right from the beginning, they may not need transplantation and may recover without any significant liver problems, including chronic liver disease."

Shrestha, principal investigator for the UNC study site, said a first-phase clinical trial conducted in the United States and Great Britain during 1999 and 2000 showed promising results. In that study, sponsored by ELAD maker Vitagen Inc., 11 of 12 (91.6 percent) of patients who had been randomized to receive treatment with the new device achieved either a successful bridge to transplantation or full recovery. In a control group of patients receiving standard care, three of seven (42 percent) achieved those benefits.

In an analysis of overall results in 25 patients, including those not listed for liver transplantation, 13 of 16 (81 percent) improved on the device, compared to only five of nine (51 percent) in the control group.

Shrestha said the U.S. Food and Drug Administration was sufficiently pleased with the results to give its nod to a second-phase trial, also sponsored by Vitagen. Safety and effectiveness, including survival at 30 days, is the main endpoint, Shrestha said.

"The primary objective is to evaluate the safety, efficacy and tolerability of the ELAD system in patients with acute hepatic [liver] failure. Our secondary objective is to evaluate the study protocol with respect to patient inclusion and exclusion criteria and to study the system’s performance with regard to endpoints." Total enrollment for this trial is between 30 and 40 patients. A larger third-phase trial may follow, with an enrollment of at least 200 people with acute liver failure.

"Currently, we don’t have very good therapies for patients with acute liver failure. That’s why we’re hoping that the new technology will make a big difference," Shrestha said. "The bottom line is to save lives."


Note: Contact Shrestha at (919) 843-9459 or (919) 966-2516 (choose option "O"), or r_shrestha@med.unc.edu.

School of Medicine contact: Les Lang, (919) 843-9687 or llang@med.unc.edu


Leslie H. Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

Bodyguards in the gut have a chemical weapon

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>